Dr. med. Sabine Seidel
Seidel S, Margold M, Kowalski T, Baraniskin A, Schroers S, Korfel A, Thiel E, Weller M, Martus P, Schlegel U. Patients with primary central nervous system lymphoma not eligible for clinical trials: prognostic factors, treatment and outcome. Cancers (Basel) 2021;13: 2934
Margold M, Seidel S, Kowalski T, Ladigan S, Baraniskin A, Schroers R, Frey AV, Schmidt-Wolf IGH, Herrlinger U, Schlegel U. The value of bone marrow biopsy for staging of patients with primary CNS lymphoma. Neuro Oncol. 2021;noab109. doi: 10.1093/neuons/noab109. Online ehead of print
Tzaridis T, Schäfer N, Weller J, Steinbach JP, Schlegel U, Seidel S, Sabel M, Hau P, Seidel C, Krex D, Goldbrunner R, Tonn JC, Grauer O, Kebir S, Schneider M, Schaub C, Vatter H, Coch C, Glas M, Fimmers R, Pietsch T, Reifenberger G, Herrlinger U, Felsberg J. MGMT promotor methylation analysis for allocating combined CCNU/TMZ chemotherapy: lessons learned from the CeTeG/NOA-09-trial. J Cancer 2021;PMID:33113214
Anton S, Margold M, Kowalski T, Miller D, Schmieder K, Schlegel U, Seidel S. Complications of intracerebroventricular chemotherapy via subgaleal reservoir in primary central nervous system lymphoma: a single-institution experience on 1247 installations in 94 consecutive patients. Hematol Oncol. 2020;PMID:33316084
Seidel S, Pels H, Schlömer S, Kowoll A, Fliessbach K, Engert A, Vogt-Schaden M, Egerer G, Reichmann H, Schackert G, Kroschinsky F, Deckert M, Herrlinger U, Klockgether T, Fimmers R, Bode U, Schmidt-Wolf I, Schlegel U. Twenty years follow-up of a pilot/phase II-trial on the Bonn protocol for primary CNS lymphoma. 2020 Neurology; accepted 23.07.2020
Seidel S, Kowalski T, Margold M, Baraniskin A, Schroers R, Martus P, Schlegel U. HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primaryCNS lymphoma: A single center series. 2020 Therapeutic Advances in Neurological Disorders; accepted 26.07.2020.
Waldera-Lupa DM, Poschmann G, Kirchgaessler N, Etemad-Parishanzadeh O, Baberg F, Brocksieper M, Seidel S, Kowalski T, Brunn A, Haghikia A, Gold R, Stefanski A, Deckert M, Schlegel U, Stühler K. A multiplex assay for the stratification of patients with primary Central Nervous System Lymphoma using targeted mass spectrometry. Cancers (Basel) 2020;12: E1732.doi:
Wiemann G, Pertz M, Kowalski T, Seidel S, Schlegel U, Thoma P. Complete response to therapy: why do primary central nervous system lymphoma patients not return to work? Journal of Neuro-Oncology 2020;Accepted
Seidel S, Schlegel U. Have treatment protocols for primary CNS lymphoma advanced in the past 10 years. Expert Rev Anticancer Ther. 2019;19: 909 - 915
Seidel S, Korfel A, Kowalski T, Margold M, Ismail F, Schroers R, Baraniskin A, Pels H, Martus P, Schlegel U. HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospectiv analysis. Neurol. Res. Pract. 2019;1:17
Margold M, Seidel S, Kowalski T, Ladigan S, Baraniskin A, Schroers R, Frey AV, Schmidt-Wolf IGH, Herrlinger U, Schlegel U. The value of bone marrow biopsy for staging of patients with primary CNS lymphoma. Neuro Oncol. 2021;noab109. doi: 10.1093/neuons/noab109. Online ehead of print
Tzaridis T, Schäfer N, Weller J, Steinbach JP, Schlegel U, Seidel S, Sabel M, Hau P, Seidel C, Krex D, Goldbrunner R, Tonn JC, Grauer O, Kebir S, Schneider M, Schaub C, Vatter H, Coch C, Glas M, Fimmers R, Pietsch T, Reifenberger G, Herrlinger U, Felsberg J. MGMT promotor methylation analysis for allocating combined CCNU/TMZ chemotherapy: lessons learned from the CeTeG/NOA-09-trial. J Cancer 2021;PMID:33113214
Anton S, Margold M, Kowalski T, Miller D, Schmieder K, Schlegel U, Seidel S. Complications of intracerebroventricular chemotherapy via subgaleal reservoir in primary central nervous system lymphoma: a single-institution experience on 1247 installations in 94 consecutive patients. Hematol Oncol. 2020;PMID:33316084
Seidel S, Pels H, Schlömer S, Kowoll A, Fliessbach K, Engert A, Vogt-Schaden M, Egerer G, Reichmann H, Schackert G, Kroschinsky F, Deckert M, Herrlinger U, Klockgether T, Fimmers R, Bode U, Schmidt-Wolf I, Schlegel U. Twenty years follow-up of a pilot/phase II-trial on the Bonn protocol for primary CNS lymphoma. 2020 Neurology; accepted 23.07.2020
Seidel S, Kowalski T, Margold M, Baraniskin A, Schroers R, Martus P, Schlegel U. HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primaryCNS lymphoma: A single center series. 2020 Therapeutic Advances in Neurological Disorders; accepted 26.07.2020.
Waldera-Lupa DM, Poschmann G, Kirchgaessler N, Etemad-Parishanzadeh O, Baberg F, Brocksieper M, Seidel S, Kowalski T, Brunn A, Haghikia A, Gold R, Stefanski A, Deckert M, Schlegel U, Stühler K. A multiplex assay for the stratification of patients with primary Central Nervous System Lymphoma using targeted mass spectrometry. Cancers (Basel) 2020;12: E1732.doi:
Wiemann G, Pertz M, Kowalski T, Seidel S, Schlegel U, Thoma P. Complete response to therapy: why do primary central nervous system lymphoma patients not return to work? Journal of Neuro-Oncology 2020;Accepted
Seidel S, Schlegel U. Have treatment protocols for primary CNS lymphoma advanced in the past 10 years. Expert Rev Anticancer Ther. 2019;19: 909 - 915
Seidel S, Korfel A, Kowalski T, Margold M, Ismail F, Schroers R, Baraniskin A, Pels H, Martus P, Schlegel U. HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospectiv analysis. Neurol. Res. Pract. 2019;1:17
- Deutsche Gesellschaft für Neurologie
- Deutsche Gesellschaft für Epilepsie
- Deutsche Gesellschaft für Klinische Neurophysiologie und Funktionelle Bildgebung
- Neuroonkologische Arbeitsgemeinschaft in der Deutschen Krebsgesellschaft
© 2024 Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH